Why should founders scrutinize control terms as closely as valuation in a term sheet?

Valuation determines dilution in the current round, but control terms such as board composition, protective provisions, and information rights determine who can block future financings, approve a sale, or remove management, and these terms persist and often compound across subsequent rounds. A MedTech founder who accepts an unfavorable board structure or broad protective provisions to secure a slightly higher valuation can find themselves unable to act quickly on a strategic acquisition offer or a pivot after a difficult trial readout. Experienced counsel typically advises founders to negotiate control terms with the same rigor as price.

How do MedTech term sheets typically incorporate milestone-based tranches?

Because MedTech financings often fund binary, high-cost events like a pivotal trial or an FDA submission, term sheets frequently structure the total committed capital into tranches that release only after specific, objectively verifiable milestones are achieved, such as IDE approval, first-patient-in, or 510(k) clearance. This lets investors share development risk with the company rather than committing all capital upfront, but it also means founders must negotiate what happens if a milestone is missed, delayed by a regulator, or achieved on a different timeline than expected. Poorly defined milestones or milestones dependent entirely on third parties like FDA are a frequent source of later dispute.

What is the most common founder mistake when negotiating a term sheet?

Signing an exclusivity or no-shop provision without a clearly bounded timeline is one of the most common mistakes, since it prevents the company from continuing to raise capital elsewhere while the lead investor completes diligence, potentially for weeks or months, with no guarantee the deal closes. Founders also commonly focus disproportionately on the headline valuation while overlooking liquidation preference stacking, participation rights, or anti-dilution mechanics that meaningfully affect actual proceeds at exit. Engaging experienced venture counsel to review the full term sheet, not just the valuation line, is standard practice for a reason.

Back to Founder & Investor Primer

Investment & FinanceStartup Lifecycle

Term Sheet

Non-binding outline of the key economic and control terms of an investment.

Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

Definition

A term sheet summarizes the principal terms of a proposed financing - valuation, amount, security type, board composition, liquidation preference, anti-dilution, protective provisions - before counsel drafts definitive documents. Most terms are non-binding, but clauses such as confidentiality, exclusivity (a no-shop period, often 30 to 60 days) and governing law are usually binding. Economic terms set what investors get, and control terms set who decides. Many US deals use the NVCA model documents as a starting point, which speeds up legal drafting.

What the regulation says

A MedTech term sheet has no dedicated regulatory regime. Its binding effect depends on applicable contract law and its wording; labeling the document non-binding does not necessarily neutralize expressly binding confidentiality or exclusivity clauses. Securities law can apply before definitive agreements are signed. The US Securities Act of 1933, enacted May 27, 1933, establishes registration requirements under Section 5. Section 4(a)(2) exempts issuer transactions not involving a public offering. A term sheet does not itself establish that a financing qualifies for an exemption. Product regulation matters when financing is conditional on development milestones. Section 520(g) of the US Federal Food, Drug, and Cosmetic Act, added by the Medical Device Amendments of 1976 on May 28, 1976, provides the statutory framework for investigational device exemptions. In the EU, Regulation (EU) 2017/745, adopted April 5, 2017 and generally applicable from May 26, 2021, sets medical-device conformity assessment requirements in Article 52, with procedures detailed in Annexes IX to XI. These requirements can inform financing milestones, but regulators do not prescribe investment tranches. Term sheets should distinguish clinical-study authorization, conformity assessment and commercial milestones rather than treating them as interchangeable regulatory approvals.

What this means in practice

In MedTech, term sheets often include milestone-based tranches tied to regulatory or clinical events (e.g., Tranche 2 releases on IDE approval). Founders should focus as much on control terms (board, protective provisions) as on valuation.

Examples

A Series B term sheet for a $40M round with a $120M pre-money, 1x non-participating preferred, and a 2-of-5 board with one independent director.

Common pitfalls

•Optimizing only for valuation and ignoring liquidation preferences, participation, or protective provisions.
•Signing exclusivity (no-shop) without a clear timeline.

Frequently asked questions

Most provisions of a venture term sheet, including valuation, board composition, and liquidation preference, are explicitly non-binding and serve only as a framework for definitive documents to be drafted by counsel. However, certain provisions are typically binding immediately, most notably confidentiality, exclusivity or no-shop clauses, and sometimes expense reimbursement, and founders who breach a signed no-shop provision while shopping the deal to other investors can face real legal consequences even though the deal terms themselves are not enforceable.

Cross-references

Contains

Sub-elements or required artefacts of this term.

Grouped by theme

Editor's picks

· Hand-selected related concepts

Investment & Finance

Board of Directors

The governing body elected by stockholders that oversees management, approves major corporate actions, and typically includes investor-designated seats after venture financing.

Investment & Finance

Liquidation Preference

Right of preferred shareholders to be paid before common in an exit.

Investment & Finance

Milestone-Based Tranche

Investment paid in installments triggered by predefined milestones.

Investment & Finance

Pro-Rata Rights

Right of an existing investor to maintain ownership percentage in future rounds.

Founder & Investor Primer

· From this learning path

Investment & Finance

Convertible Note

Short-term debt that converts into equity at a future financing round.

Adjacent lesson

Investment & Finance

Valuation Cap

Maximum company valuation at which a SAFE or note converts to equity.

Adjacent lesson

Investment & Finance

Capitalization Table(Cap Table)

Ledger of all securities issued by a company and who owns them.

Investment & Finance

Due Diligence

Investigation of a company before an investment, financing, or acquisition.

Cited by

Where this term appears across MedTech Terms.

Learning paths (1)

Founder & Investor PrimerLesson 9 of 16

Ecosystems (1)

Startup Lifecycle

Latest in MedTech

Sources

3 sources

Every citation below opens the original document. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

Tier 4Trade press and expert commentary· 3

Link health: 3 verified· last checked 2026-06-20

NVCA·1SVB·1PitchBook·1

Inline markers like [1] jump to the matching reference above.

My progress

All terms0 / 513

Investment & Finance0 / 47

Saved on this device, and to your account when signed in. View studied terms

Full glossary

Browse all terms A to Z, each with a short definition.

On this term

Category: Investment & Finance
Sources: 3
Updated: 5/5/2026

Compare with another term

Learn in 60 seconds

Non-binding outline of the key economic and control terms of an investment.

·In MedTech, term sheets often include milestone-based tranches tied to regulatory or clinical events (e.g., Tranche 2 releases on IDE approval).
·Founders should focus as much on control terms (board, protective provisions) as on valuation.
·Most terms are non-binding, but clauses such as confidentiality, exclusivity (a no-shop period, often 30 to 60 days) and governing law are usually binding.

Remember this

Watch out: Optimizing only for valuation and ignoring liquidation preferences, participation, or protective provisions.

Related terms

You may also need

Auto-suggested from Investment & Finance and shared keywords.

All Investment & Finance terms